Abbott Laboratories vs Medtronic
Abbott Laboratories reported revenue of $44.3 billion in fiscal 2025, 1.2 times Medtronic's $36.4 billion in fiscal 2026. Abbott Laboratories' revenue grew 5.7% in its latest year, and Medtronic's grew 8.4%. Abbott Laboratories had an operating margin of 18.2%, against 17.8% at Medtronic. Free cash flow was $7.4 billion at Abbott Laboratories and $5.4 billion at Medtronic. Their fiscal years end in different months (December 31 and April 24), so the periods don't line up exactly.
Side by side
| Abbott Laboratories | Medtronic | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Apr 24, 2026 |
| Revenue | $44.3B | $36.4B |
| Revenue growth | 5.7% | 8.4% |
| Revenue growth a year, last 5 years | 5.1% | 3.8% |
| Gross margin | 56.4% | 65.0% |
| Operating margin | 18.2% | 17.8% |
| Net margin | 14.7% | 13.2% |
| Free cash flow | $7.4B | $5.4B |
| Free cash flow margin | 16.7% | 14.9% |
| Return on capital | 11.2% | 7.7% |
| Net debt to EBITDA | 0.4x | 1.8x |
| Dividends and buybacks | $5.0B | $4.7B |
| Change in diluted share count | 0.0% | −0.1% |
| Last close | $104.88 | $94.79 |
| P/E at the last close | 29.3× | 23.3× |
| Insider trades, last 12 months | bought $4.4 million, sold $47.5 million | sold $14.7 million |
| Piotroski F-score | 6 of 9 | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Abbott LaboratoriesMedtronic
Operating margin
Percent of revenue
Abbott LaboratoriesMedtronic
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Abbott LaboratoriesMedtronic
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Abbott Laboratories and Medtronic pages.